The big re­vamp at Glax­o­SmithK­line R&D in­cludes a new col­lab­o­ra­tion on AI

A few weeks ago, when Glax­o­SmithK­line said it had re­cruit­ed Pfiz­er vet Tony Wood to run the plat­form tech and sci­ence group in the phar­ma R&D op­er­a­tion, the com­pa­ny not­ed that he was tak­ing the place of John Bal­doni, a se­nior re­search ex­ec who was launch­ing a new ef­fort to use ar­ti­fi­cial in­tel­li­gence tech­nol­o­gy to ramp up a new ap­proach to drug iden­ti­fi­ca­tion and de­vel­op­ment.

This morn­ing, we learned that Bal­doni has de­cid­ed to team with In­sil­i­co Med­i­cine out of Bal­ti­more, which al­so re­cent­ly scored a joint ven­ture with an up­start an­ti-ag­ing biotech — Ju­ve­nes­cence — be­ing launched by UK bil­lion­aire Jim Mel­lon and some high-pro­file biotech col­leagues he’s been work­ing with. The deal comes just a few weeks af­ter Bal­doni struck a pact with Ex­sci­en­tia, an­oth­er AI com­pa­ny based in the UK.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.